Joint Accreditation Statement
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
Postgraduate Institute of Medicine designates this continuing education activity for 4.0 contact hours (0.40 CEUs) of the Accreditation Council for Pharmacy Education.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 4.0 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.
American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. The existence or absence of COI for everyone in a position to control educational content will be disclosed to participants prior to the start of each activity.
Avoid Fraudulent ACI Registration Websites
Recently, the SITC office received communication about a fraudulent registration website for one of our ACI programs. To help ensure others don’t mistakenly register on an unauthorized, third-party website, we're proactively informing you to ensure you’re able to safely register for the event through the official SITC website, and so that you can confirm the communication you receive is truly from SITC.
All official forthcoming ACI registration information will come from an email address ending in @sitcancer.org.
If you have any questions, please contact the SITC office at firstname.lastname@example.org or 414-271-2456.
Americans with Disabilities Act
Event staff will be glad to assist you with any special needs (i.e., physical, dietary, etc). Please contact SITC Staff prior to the live event at (414) 271-2456 or via email email@example.com.
The ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc. (as of 1/19/2022)
The 2021-2022 Advances in Cancer Immunotherapy™ series is brought to you in collaboration with the Association of Community Cancer Centers, Advances Practitioner Society for Hematology and Oncology, and Hematology/Oncology Pharmacy Association. This program is provided in collaboration with the American Academy of Emergency Medicine.